CME Group
CME
$281.94
-1.09%
CME Group Inc. is a global financial markets company that operates derivatives and futures exchanges, including the Chicago Mercantile Exchange, Chicago Board of Trade, NYMEX, and COMEX. It is the world's leading and most diverse derivatives marketplace, offering trading in interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals. The current investor narrative is heavily focused on the company's role as a critical financial infrastructure provider during periods of heightened market volatility and interest rate uncertainty, with recent news highlighting how the Federal Reserve's commitment to fighting inflation may sustain elevated trading volumes. Additionally, the company's exceptional cash flow generation and shareholder returns, evidenced by a substantial annual variable dividend declaration, are central to the investment debate, positioning CME as a defensive growth story within financial services.…
CME
CME Group
$281.94
Related headlines
Investment Opinion: Should I buy CME Today?
Rating & Thesis: CME is a Hold. The core thesis is that the stock represents a high-quality, defensive cash compounder trading at a full valuation, offering limited near-term capital appreciation upside but a secure and attractive yield. This aligns with a mixed but cautious analyst consensus that includes recent downgrades.
Supporting Evidence: The hold rating is supported by four key data points. First, valuation is rich at a 24.3x trailing P/E, a premium to its historical range. Second, while revenue growth is steady at 8.1% YoY, it is not explosive. Third, exceptional profitability (70.8% net margin) and cash flow ($4.19B FCF) underpin the safety of its 4.0% yield. Finally, implied upside to analyst targets (using the forward P/E of 22.1x and estimated EPS of $15.70 to derive a ~$347 price) suggests only moderate potential from current levels, especially when weighed against recent price weakness.
Risks & Conditions: The two biggest risks to the thesis are a faster-than-expected decline in trading volumes compressing earnings, and a sector rotation away from low-beta, high-multiple stocks causing valuation derating. This Hold would upgrade to a Buy if the P/E multiple compressed meaningfully below 22x (closer to its historical average) or if revenue growth re-accelerated sustainably above 10% YoY. It would downgrade to a Sell if quarterly revenue growth turned negative or if the dividend sustainability came into question. The stock is currently fairly valued to slightly overvalued relative to its own history, but the premium is partially justified by its exceptional quality and yield.
Sign up to view all
CME 12-Month Price Forecast
CME is a high-quality company in a low-growth, defensive wrapper. Its investment appeal is bifurcated: for income-oriented investors, the secure 4.0% yield and strong balance sheet are highly attractive. For growth-oriented investors, the rich valuation and dependence on cyclical trading volumes are significant headwinds. The neutral stance reflects this balance—the stock is not cheap enough to be a compelling buy for appreciation, nor risky enough to warrant a sell given its defensive characteristics. The stance would upgrade to bullish on a meaningful pullback (towards $270) that improves the risk/reward, or downgrade to bearish if quarterly revenue growth turns negative, signaling the volume decline thesis is materializing.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CME Group's 12-month outlook, with a consensus price target around $366.52 and implied upside of +30.0% versus the current price.
Average Target
$366.52
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$226 - $367
Analyst target range
CME is covered by 7 analysts, indicating solid institutional interest. The consensus sentiment appears mixed but leans positive, with recent actions including a downgrade from 'Buy' to 'Hold' by Argus Research in March 2026, but also an upgrade from 'Hold' to 'Buy' by TD Cowen in January 2026. Other major firms like Morgan Stanley maintain an 'Overweight' rating, while Barclays holds an 'Equal Weight' and JP Morgan an 'Underweight'. The average target price is not explicitly provided in the data, but analyst estimates point to an average EPS forecast of $15.70 for the coming period, which, when combined with the forward P/E of 22.1x, implies a target price in the mid-$340s, suggesting meaningful upside from the current price of $285.06. The target price range, inferred from the estimated EPS low of $14.99 and high of $16.25, would be wide, reflecting differing views on interest rate volatility and trading volume sustainability. The high-end targets likely assume continued strong volumes and multiple expansion, while the low-end targets may factor in potential normalization of activity and margin pressures. The mix of ratings and a likely wide target range signals moderate uncertainty and debate among analysts regarding the near-term catalysts and macroeconomic sensitivity of CME's earnings.
Bulls vs Bears: CME Investment Factors
The bull case for CME is anchored in its exceptional quality: unparalleled profitability, a fortress balance sheet, and reliable cash flows that fund substantial shareholder returns. The bear case centers on its premium valuation, recent market underperformance, and cyclical dependence on trading volumes. Currently, the bull side has stronger evidence due to the company's defensive, cash-generative business model which is precisely what investors seek during periods of macro uncertainty. The single most important tension in the investment debate is whether CME's premium valuation (24.3x P/E) is justified by its defensive growth and cash return profile, or if it will compress as market sentiment shifts away from defensive names towards higher-beta growth stocks.
Bullish
- Exceptional Profitability & Margins: CME's Q4 2025 net margin reached 70.8%, with an operating margin of 64.9%. This reflects the asset-light, high-margin nature of its exchange and clearing operations, providing significant pricing power and cash flow stability.
- Strong Cash Flow & Shareholder Returns: The company generated $4.19B in trailing free cash flow, supporting a generous 4.0% dividend yield and a 97.2% payout ratio. Recent news highlights a $4B total payout, demonstrating a firm commitment to returning capital.
- Robust Balance Sheet & Low Risk: CME has a fortress balance sheet with a debt-to-equity ratio of 0.13 and a current ratio of 92.97. This immense liquidity and minimal leverage provide a significant buffer against financial stress and operational volatility.
- Defensive Beneficiary of Market Volatility: Recent news highlights the Federal Reserve's commitment to fighting inflation, which sustains interest rate uncertainty and trading volumes. CME's role as critical financial infrastructure makes it a direct beneficiary of such macro conditions.
Bearish
- Premium Valuation Relative to History: The stock trades at a trailing P/E of 24.3x, above its recent historical average in the low-20s. This premium valuation leaves limited room for multiple expansion and increases sensitivity to earnings disappointments.
- Recent Underperformance vs. Broader Market: CME has a 1-year relative strength of -22.31% and is down 3.02% over the past month while the SPY rallied 8.7%. This suggests the stock is not participating in the market's risk-on move, raising concerns about near-term momentum.
- High Dependence on Sustained Trading Volumes: Revenue is heavily reliant on clearing and transaction fees. A significant decline in market volatility or a shift to a lower-interest-rate environment could pressure volumes and growth, as implied by the mixed analyst sentiment.
- Elevated Dividend Payout Ratio: A 97.2% payout ratio, while supported by strong cash flow, leaves minimal room for error. A sustained earnings decline could pressure the company's ability to maintain its current level of shareholder returns.
CME Technical Analysis
The stock is in a sustained uptrend over the past year, with a 1-year price change of 8.28%, though it has notably underperformed the broader market, as indicated by its negative 1-year relative strength of -22.31%. As of the latest close at $285.06, the stock is trading at approximately 86.6% of its 52-week high of $329.16, indicating it is near the upper end of its annual range but has retreated from its peak, suggesting some consolidation after a strong run. Recent momentum has turned negative, with the stock declining 3.02% over the past month, diverging from the positive 0.82% 3-month return and signaling a potential short-term pullback or loss of momentum. This recent weakness is underscored by a low beta of 0.296, indicating the stock is significantly less volatile than the market, which has rallied 8.7% over the same 1-month period, highlighting CME's recent defensive underperformance. Key technical support is anchored at the 52-week low of $257.17, while the recent high near $329 serves as formidable resistance; a decisive break above resistance would signal a resumption of the primary uptrend, whereas a break below support could indicate a deeper correction. The stock's low beta suggests it is a relatively stable holding, but its recent underperformance versus the SPY's strong rally indicates it is not participating in the broader market's risk-on move, which may concern momentum investors.
Beta
0.30
0.30x market volatility
Max Drawdown
-13.6%
Largest decline past year
52-Week Range
$257-$329
Price range past year
Annual Return
+5.9%
Cumulative gain past year
| Period | CME Return | S&P 500 |
|---|---|---|
| 1m | -4.0% | +12.8% |
| 3m | -0.9% | +2.8% |
| 6m | +7.8% | +4.0% |
| 1y | +5.9% | +29.9% |
| ytd | +4.5% | +4.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CME Fundamental Analysis
CME's revenue trajectory shows steady growth, with Q4 2025 revenue of $1.65 billion representing an 8.1% year-over-year increase, and sequential quarterly revenue has demonstrated resilience, moving from $1.48B in Q1 2025 to the recent $1.65B. The primary growth driver is clearing and transaction fees, which contributed $1.33 billion in the latest period, underscoring the core exchange business's strength. This consistent top-line expansion, amidst a volatile macro environment, supports the thesis of CME as a beneficiary of increased hedging and trading activity. The company is highly profitable, with Q4 2025 net income of $1.17 billion and a robust net margin of 70.8%, while its gross margin of 85.4% reflects the asset-light, high-margin nature of its exchange and clearing operations. Profitability metrics are exceptionally strong, with a trailing Return on Equity (ROE) of 14.1% and an operating margin of 64.9%, indicating efficient operations and significant pricing power within its oligopolistic market structure. CME possesses an exceptionally strong balance sheet, highlighted by a minuscule debt-to-equity ratio of 0.13 and a staggering current ratio of 92.97, indicating immense liquidity and virtually no short-term solvency risk. The company generates substantial cash, with trailing twelve-month free cash flow of $4.19 billion, supporting its generous shareholder return policy, including a dividend payout ratio of 97.2% and a dividend yield of 4.0%, which is funded by its powerful cash conversion.
Quarterly Revenue
$1.6B
2025-12
Revenue YoY Growth
+0.08%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$4.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CME Overvalued?
Given CME's substantial net income of $1.17 billion in Q4 2025, the primary valuation metric is the Price-to-Earnings (P/E) ratio. The stock trades at a trailing P/E of 24.3x and a forward P/E of 22.1x, with the forward multiple's discount to the trailing figure suggesting analysts anticipate modest earnings growth. Compared to its own historical range, the current trailing P/E of 24.3x sits above the multi-quarter average visible in the historical data, which has frequently been in the low-20s, indicating the stock is trading at a premium to its recent historical valuation. This elevated multiple reflects the market's confidence in the stability and quality of CME's earnings stream, as well as its defensive characteristics. When benchmarked against typical industry averages for financial data & exchanges, a trailing P/E in the mid-20s often represents a premium, which for CME is justified by its dominant market position, exceptional margins (64.9% operating margin), and strong return on equity (14.1%). The premium valuation is supported by the company's asset-light model and reliable cash flows, which allow for consistent and substantial capital returns to shareholders.
PE
24.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~37x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CME's primary financial risk is not solvency—its balance sheet is pristine—but earnings volatility tied to trading activity. While revenue grew 8.1% YoY in Q4, this growth is contingent on sustained market volatility and interest rate uncertainty. The high dividend payout ratio of 97.2%, though funded by robust cash flow, represents a commitment that could be challenged if earnings decline materially. There is also concentration risk in its revenue stream, with clearing and transaction fees constituting the vast majority of sales, making top-line performance highly correlated to global trading volumes.
Market & Competitive Risks: The stock trades at a premium valuation (24.3x trailing P/E) compared to its own recent history, creating valuation compression risk if growth decelerates or investor appetite for defensive, high-multiple stocks wanes. Its low beta of 0.296 indicates low market correlation, which can be a detriment in strong bull markets, as evidenced by its recent 22% underperformance versus the SPY over the past year. Competitive risks are structural but low, given CME's oligopolistic market position; the greater threat is technological disruption or regulatory changes impacting derivatives trading. Recent news highlighting the Fed's inflation fight is a double-edged sword—it supports volumes now but poses a risk when the rate cycle eventually turns.
Worst-Case Scenario: The most damaging scenario would be a rapid normalization of interest rates coupled with a prolonged period of low market volatility, sharply reducing trading volumes and clearing fees across CME's key product lines. This could trigger multiple compression as its 'volatility beneficiary' narrative unwinds, alongside potential earnings misses leading to dividend growth stagnation. Quantifying the realistic downside, the stock could re-test its 52-week low of $257.17, representing a potential loss of approximately -10% from the current price of $285.06. A more severe bear case, incorporating a lower earnings multiple, could see a decline towards the $240-$250 range, implying a downside of -12% to -16%.
FAQ
The key risks are, in order of severity: 1) Volume/Rate Risk: Earnings are tied to trading volumes, which could decline sharply if market volatility subsides or the Fed cuts rates (recent news highlights this dependency). 2) Valuation Risk: The premium P/E multiple of 24.3x could compress if growth slows or investor sentiment shifts. 3) Market Correlation Risk: Its low beta (0.296) means it may underperform significantly in strong bull markets, as seen in its -22% relative strength over the past year. 4) Dividend Sustainability Risk: While currently secure, the 97.2% payout ratio leaves little cushion for a significant earnings downturn.
The 12-month forecast presents three scenarios. The Base Case (60% probability) sees the stock trading between $320 and $347, driven by meeting EPS estimates of $15.70 and maintaining its current valuation. The Bull Case (25% probability) targets $347 to $365, requiring sustained high volatility and earnings beats. The Bear Case (15% probability) warns of a drop to the $257-$300 range if trading volumes collapse and the P/E multiple contracts. The base case is most likely, assuming a gradual normalization of market conditions but no severe downturn. The key assumption is that CME's earnings prove resilient enough to support its premium multiple.
CME stock is fairly valued to slightly overvalued relative to its own recent trading history. Its trailing P/E of 24.3x is above its multi-quarter average, which has frequently been in the low-20s. This premium is partially justified by the company's exceptional quality—64.9% operating margins, 14.1% ROE, and minimal debt—which commands a higher multiple. Compared to typical financial exchange peers, a mid-20s P/E often represents a premium. The current valuation implies the market expects CME to maintain its high profitability and continue generating steady, low-volatility earnings growth, leaving little margin for error.
CME is a good buy for a specific type of investor: one seeking a defensive, high-yield component for a portfolio with a long-term horizon. The 4.0% dividend yield is well-supported by $4.19B in annual free cash flow and a fortress balance sheet. However, for investors seeking capital appreciation, the current valuation at a 24.3x P/E is full, and recent underperformance versus the market (-22% over one year) suggests weak momentum. The stock is a 'good buy' under the condition that an investor prioritizes income and capital preservation over explosive growth, and is comfortable with the stock's sensitivity to trading volumes.
CME is unequivocally more suitable for a long-term investment horizon. Its value proposition is as a compounding cash flow machine and reliable income generator, benefits that accrue over years. The stock's low beta (0.296) and high yield make it a poor candidate for short-term trading, as it lacks the volatility and momentum typically sought for quick gains. Its recent 3% decline over the past month amid a market rally underscores its defensive, non-cyclical behavior. A minimum holding period of 3-5 years is suggested to fully realize the benefits of dividend compounding and to ride out any periods of valuation compression related to the interest rate cycle.